squamous cell carcinoma, adenosquamous
carcinoma, mixed adenoneuroendocrine carcinoma, high-grade neuroendocrine carcinoma and undifferentiated carcinoma, were excluded.
We reflexively test all nonsquamous non-small cell lung carcinomas, including adenocarcinomas, combined adenosquamous
carcinomas, and non-small cell carcinomas, not otherwise specified, for EGFR mutations and ALK gene rearrangements.
Differences in the ARID-1 alpha expressions in squamous and adenosquamous
carcinomas of uterine cervix.
Clear cell adenosquamous
carcinoma of the cervix: a case report with discussion of the differential diagnosis.
Study participants were women with a mean age of 46 years with stage IA1, IA2, or IB1 cervical cancer, with most (91.9%) having IB1 disease, and either squamous cell carcinoma, adenocarcinoma, or adenosquamous
Most patients (67 [78.8%]) had squamous cell carcinoma while 18 (21.2%) had adenocarcinoma or adenosquamous
Synchronous tumors that are regarded as metastases are usually of high histological grade, for example, adenosquamous
carcinomas, mixed Mullerian tumors, and non-endometrioid carcinomas (serous and clear cell).
According to histopathological examination, squamous cell carcinoma was determined in 88 (64.7%) cases, adenocarcinoma in 41 (30.1%) cases, adenosquamous
cell carcinoma in 4 (2.9%) cases, large cell carcinoma in 2 (1.5%) cases, and bronchoalveolar carcinoma in 1 (0.8%) case.
Histopathological examination revealed adenosquamous
carcinoma and multiple hamartomatous polyps.
carcinoma arising in a hidradenoma papilliferum, with rapidly fatal outcome: case report.
Inclusion criteria were (a) biopsy-documented invasive cervical cancer by a loop electrosurgical excision procedure (LEEP) or a cone biopsy or punch biopsy; at least 7 days after a biopsy, MRI was performed to prevent false-positive findings due to biopsy inflammation, (b) clinical FIGO stage IA, IB, or IIA, (c) histology of squamous cell carcinoma or adenocarcinoma or adenosquamous
carcinoma, (d) no medical or surgical contraindications to radical hysterectomy with pelvic lymph node dissection (PLND) with or without paraaortic lymph node sampling (PALS) and dissection (PLND), (f) having an Eastern Cooperative OncologyGroup (ECOG) performance status of 0-1, and (g) provided informed consent.